Indian pharmaceutical companies are likely to see profit margins cool off in FY27 after years of record highs. While the domestic market remains steady, increased competition in the US and rising input costs are weighing on export profitability. Investors should monitor how effectively firms can offset these challenges with new high-value product launches.
What Happened
Indian pharmaceutical manufacturers are shifting gears after a period of exceptional profitability. Following several years where companies enjoyed record-high profit margins—driven largely by selling high-value, limited-competition drugs in the US—the sector is now bracing for a more moderate FY27. This cooling effect is due to a combination of expiring product exclusive rights and higher operating costs. While the March 2026 quarterly results already showed signs of this softening, the trend is expected to persist as the industry navigates a more challenging pricing environment.
The US Market Shift
For years, the 'easy' growth for many Indian drug exporters came from launching complex generic drugs with very few competitors. This allowed them to charge higher prices and maintain thick margins. However, as these products lose their exclusivity, market competition increases, which naturally pulls down prices. A primary example is the generic version of the oncology drug Revlimid, which has seen its contribution to profit margins decline as more competitors have entered the space.
Additionally, companies are facing pressure from rising input costs, including raw materials and logistics, often tied to global geopolitical conditions. These factors are squeezing operating margins, making it difficult for firms to replicate the earnings growth seen in previous years.
Divergence in Performance
Not all companies are feeling the heat in the same way. The March 2026 results highlighted a clear split in performance among major finished-dosage exporters. While many firms reported sluggish growth in the US, companies such as Lupin and Zydus Lifesciences managed to outperform their peers during this period. Conversely, giants like Sun Pharma have faced pressure on their core generic business, and Cipla has navigated supply chain issues that impacted its US performance. This variance suggests that individual company strategies—such as how quickly they can launch new, unique products—are becoming more important than sector-wide tailwinds.
The Domestic Buffer
While export markets face headwinds, the Indian Pharmaceutical Market (IPM) has emerged as a crucial support pillar. Domestic sales have maintained a steady upward trend, with growth rates hovering around 10 percent in April and May 2026. This resilience is attributed to consistent price increases, a strong performance from new product launches, and a contribution from high-demand therapies, including GLP-1 drugs. For many investors, the domestic market is currently serving as a safety net that helps smooth out the volatility coming from international operations.
What Investors Should Track Next
Looking ahead, the primary monitorable is how companies manage the transition from older, high-margin products to their next wave of launches. Investors may track:
- New Product Pipelines: The speed and success rate of launching complex, high-value drugs will be critical to offsetting price erosion in legacy generics.
- Margin Sustainability: While margins are expected to moderate, the key question is whether they will stabilize above historical averages or drift closer to long-term norms.
- Operating Costs: Keep an eye on management commentary regarding raw material prices and their ability to pass on costs to customers.
- US vs. Domestic Mix: Companies that can balance their portfolio with robust domestic growth may be better positioned to handle export volatility.